Belite Bio, Inc (BLTE)

Market Cap	1.33B
Revenue (ttm)	n/a
Net Income (ttm)	-31.63M
Shares Out	29.79M
EPS (ttm)	-1.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,555
Open	42.05
Previous Close	42.44
Day's Range	41.88 - 44.97
52-Week Range	11.00 - 48.60
Beta	-1.53
Analysts	Strong Buy
Price Target	50.25 (+11.74%)
Earnings Date	May 13, 2024

About BLTE

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy tha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2022
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: BLTE

Analyst Forecast

According to 5 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price forecast is $50.25, which is an increase of 11.74% from the latest price.

Price Target

$50.25

(11.74% upside)

Analyst Consensus: Strong Buy